Health Care/Hospital
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and developmentCRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times.Over the past 20 year...
2024-03-11 20:30
1164
ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
OSAKA, Japan, March 11, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it entered into a five-year, university-wide strategic research alliance agreement withHarvard University (Cambridge, MA, USA; "Harvard") aiming at v...
2024-03-11 20:00
1206
TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
* TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab * TU2218 demonstrated a favorable safety and a synergetic effect with immuno-oncology drugs in preclinical studies BOSTON and SEONGNAM, South Korea, March 11, 2024 /PRNewswire/ -- TiumBio Co.,...
2024-03-11 20:00
1120
AirNet Announces Changes in the Board of Directors
BEIJING, March 11, 2024 /PRNewswire/ -- AirNet Technology Inc., formerly known as AirMedia Group Inc. (the "Company") (Nasdaq: ANTE), today announced changes in its board of directors (the "Board"). Mr. Dong Wen has tendered resignation as an independent director of the Company, a member of the ...
2024-03-11 16:00
1197
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of...
2024-03-11 08:10
1068
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2 trial of the highly selective or...
2024-03-08 23:24
1542
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate cancer (PC) lesions in patients with biochemical recurrence (BCR). * In trial participants where standard of care (SOC) imagin...
2024-03-08 22:02
1635
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or ...
2024-03-08 22:00
1719
Wellysis and Artella Solutions Launch Innovative Remote Cardiac Monitoring Service in the US.
SEOUL, South Korea, March 8, 2024 /PRNewswire/ -- Wellysis, a digital
healthcare company spun off from Samsung, has announced the launch of remote
cardiac monitoring service in the US in partnership with Artella Solutions
(ARTELLA).
2024-03-08 22:00
2514
TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency
NANJING, China and GAITHURSBURG, Md., March 8, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus ph...
2024-03-08 21:00
2436
Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China
WUXI, China, March 7, 2024 /PRNewswire/ -- Silk Road Medical (NASDAQ: SILK), a medical device company based inCalifornia USA and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products, ENROUTE® Transcarotid Neuroprotection System and ENROUTE® T...
2024-03-08 10:00
1212
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Admi...
2024-03-08 10:00
1196
Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry
WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items of...
2024-03-07 22:00
1217
Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions
HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market inChina, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developi...
2024-03-07 15:04
1201
Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands
NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. OnDecember 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well ...
2024-03-06 21:37
1051
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
--CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity-- NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innova...
2024-03-06 21:00
1002
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...
2024-03-06 18:07
1598
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...
2024-03-06 08:59
2664
Datasea Expects Approximately 1,128% Revenue Growth in 2024
BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...
2024-03-05 23:45
2625
Laifen Launches the Laifen Wave Electric Toothbrush, a Revolutionary New Oral Health and Wellness Experience
Laifen's Newest Self-Care Innovation is Now Available to Purchase in the U.S.
HONG KONG, March 5, 2024 /PRNewswire/ -- Laifen
2024-03-05 22:00
1097
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
Animated Life in Yunnan
[Picked up by 275 media titles]
2024-04-18 14:00
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
Most Read
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6410
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6342
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
2024-04-12 20:08
4528
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3796